Seres Therapeutics Unveils Preclinical Data for IBD Candidate SER-603 at DDW 2026
Event summary
- Seres Therapeutics presented preclinical data for SER-603, a next-generation live biotherapeutic for inflammatory bowel disease (IBD), at DDW 2026.
- The poster was selected as a 'Poster of Distinction' at the conference.
- SER-603 is designed to modulate the gastrointestinal microbiome and support mucosal barrier integrity.
- The company is advancing SER-603 through IND-enabling activities and exploring potential collaborators for clinical development.
The big picture
Seres Therapeutics' presentation of preclinical data for SER-603 at DDW 2026 highlights the company's focus on developing next-generation live biotherapeutics for IBD. The data suggests a potential shift in the treatment paradigm from immunosuppression to targeted microbial modulation. The company's strategic focus on integrating clinical datasets and translational models underscores its commitment to precision medicine in the microbiome space. The success of SER-603 could position Seres as a key player in the evolving landscape of IBD therapies.
What we're watching
- Clinical Development
- The pace at which Seres Therapeutics advances SER-603 through IND-enabling activities and secures collaborators for clinical trials.
- Market Differentiation
- Whether SER-603's unique design and biomarker-driven patient stratification can differentiate it in the competitive IBD treatment landscape.
- Financial Stability
- How Seres Therapeutics manages its financial runway and secures additional funding to support its pipeline.
Related topics